Evinacumab significantly reduced fasting triglycerides (TGs) but the response was highly variable and needs further investigation, including the role of genetics.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
